Market By Type, Industry Verticals, And Country | Forecast 2021-2028
Triton’s report on the Asia-Pacific non-alcoholic steatohepatitis (NASH) biomarker market insinuates that the market is projected to experience growth at 23.71% of CAGR over the examined phase 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The countries considered in this market include:
•       India
•       China
•       Japan
•       Australia & New Zealand
•       South Korea
•       ASEAN countries
•       Rest of APAC
The reviewed market’s growth in the region is primarily due to the advancements in the healthcare sector, along with the rising prevalence of NASH. Moreover, the growing healthcare awareness in developing nations, such as India and China, is also estimated to fuel the NASH biomarker market’s growth across the Asia-Pacific region.
In China, the rising prevalence of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease has increased the need for effective medical treatments. Here, there has been tremendous growth in the occurrence of NAFLD among the Chinese population over the past few years. Moreover, the growing incidence rate of obesity and metabolic issues is anticipated to increase the number of patients suffering from fatty liver diseases. This has resulted in several companies concentrating on expanding operations in the NASH market. For instance, Terns Pharma commenced clinical trials for NASH. Therefore, such measures are likely to fuel the growth of the non-alcoholic steatohepatitis biomarker market in China.
Similarly, over the years, Japan observed a significant rise in the occurrence of NASH in morbidly obese patients. This led to the augment of early interventions to tackle the rising cases. Moreover, the Japanese government is taking steps to spread awareness pertaining to NASH among the country’s population, which is expected to supplement the NASH biomarker market’s progress across Japan.
Zydus Cadila is involved in manufacturing pharmaceutical products for several segments, such as respiratory, pain management, women’s healthcare, dermatology, and gastrointestinal, among others. It produces intermediates and APIs, including chemicals and bulk actives. Besides, Cadila is developing a formulation for abbreviated new drug application candidates. The company has operations in multiple countries, with headquarters based in Ahmedabad, India.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
1. ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. KEY INSIGHTS
2.1.1. DEMAND FOR NASH BIOMARKERS
2.1.2. UNMET MEDICAL NEEDS
2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR LANDSCAPE
2.6. KEY MARKET STRATEGIES
2.6.1. CONTRACTS & PARTNERSHIPS
2.6.2. BUSINESS EXPANSIONS & DIVESTITURES
2.6.3. ACQUISITIONS & MERGERS
2.6.4. NEW PRODUCT LAUNCHES
2.7. MARKET DRIVERS
2.7.1. RISING PREVALENCE OF NASH
2.7.2. INCREASING INCIDENCE RATE OF METABOLIC COMORBIDITIES
2.8. MARKET RESTRAINTS
2.8.1. SIDE-EFFECTS OF NASH THERAPEUTICS
2.8.2. UNAVAILABILITY OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
2.9. MARKET OPPORTUNITIES
2.9.1. GROWTH OPPORTUNITIES IN DEVELOPING REGIONS
2.9.2. RISE IN AWARENESS PERTAINING TO NON-ALCOHOLIC FATTY LIVER DISEASE
3. ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY TYPE
3.1. SERUM BIOMARKER
3.2. HEPATIC FIBROSIS BIOMARKER
3.3. APOPTOSIS BIOMARKER
3.4. OXIDATIVE STRESS BIOMARKER
3.5. OTHER TYPES
4. ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY INDUSTRY VERTICALS
4.1. PHARMA & CRO INDUSTRY
4.2. DIAGNOSTIC LAB
4.3. ACADEMIC RESEARCH KEY
4.4. HOSPITAL
5. ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - COUNTRY OUTLOOK
5.1. CHINA
5.2. JAPAN
5.3. AUSTRALIA & NEW ZEALAND
5.4. INDIA
5.5. SOUTH KOREA
5.6. ASEAN COUNTRIES
5.7. REST OF ASIA-PACIFIC
6. COMPETITIVE LANDSCAPE
6.1. ALLERGAN
6.2. ASTRAZENECA
6.3. BRISTOL MYERS SQUIBB COMPANY
6.4. GENFIT SA
6.5. GILEAD SCIENCES INC
6.6. MADRIGAL PHARMACEUTICALS
6.7. MERCK & CO
6.8. NOVARTIS AG
6.9. NOVO NORDISK
6.10. PFIZER INC
6.11. SIEMENS HEALTHINEERS
6.12. VIKING THERAPEUTICS
6.13. ZYDUS CADILA
7. RESEARCH METHODOLOGY & SCOPE
7.1. RESEARCH SCOPE & DELIVERABLES
7.1.1. OBJECTIVES OF STUDY
7.1.2. SCOPE OF STUDY
7.2. SOURCES OF DATA
7.2.1. PRIMARY DATA SOURCES
7.2.2. SECONDARY DATA SOURCES
7.3. RESEARCH METHODOLOGY
7.3.1. EVALUATION OF PROPOSED MARKET
7.3.2. IDENTIFICATION OF DATA SOURCES
7.3.3. ASSESSMENT OF MARKET DETERMINANTS
7.3.4. DATA COLLECTION
7.3.5. DATA VALIDATION & ANALYSIS
TABLE 1:Â Â Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 2:Â Â Â Â Â Â VENDOR LANDSCAPE
TABLE 3:Â Â Â Â Â Â LIST OF CONTRACTS & PARTNERSHIPS
TABLE 4:Â Â Â Â Â Â LIST OF BUSINESS EXPANSIONS & DIVESTITURES
TABLE 5:Â Â Â Â Â Â LIST OF ACQUISITIONS & MERGERS
TABLE 6:Â Â Â Â Â Â LIST OF NEW PRODUCT LAUNCHES
TABLE 7:Â Â Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 8:Â Â Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 9:Â Â Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
FIGURE 1:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 2:    PORTER’S FIVE FORCES ANALYSIS
FIGURE 3:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2020 & 2028 (IN %)
FIGURE 4:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 5:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 6:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 7:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 8:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)
FIGURE 9:Â Â Â Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)
FIGURE 10:Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)
FIGURE 11:Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)
FIGURE 12:Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)
FIGURE 13:Â ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)
FIGURE 14:Â CHINA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 15:Â JAPAN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 16:Â AUSTRALIA & NEW ZEALAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 17:Â INDIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 18:Â SOUTH KOREA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 19:Â ASEAN COUNTRIES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 20:Â REST OF ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)